| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.02B | -20.6% |
| Gross profit | ¥0.02B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | -69.0% |
| Gross margin | 82.8% | Net margin 10.9% |
| Revenue Q/Q | -50.4% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.00B | 17.2% |
| R&D | ¥0.01B | 28.3% |
| SG&A | ¥0.01B | 49.4% |
| Tax & other | ¥-0.00B | -0.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies